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        Several studies have investigated the eff  ects  of 
amyloid      protein (A    ) in the pathogenesis of 
Alzheimer  ’  s disease (AD). A     accumulates as am-
yloid in senile plaques, in the walls of cerebral 
blood vessels, and in more diff  use immunoreac-
tive deposits in the brains of patients with AD. 
This accumulation has been implicated in a path-
ological cascade that ultimately results in neuronal 
dysfunction and cell death (  1, 2  ). Multiple A     
species with varying N and C termini are gener-
ated from the amyloid      protein precursor (APP) 
through sequential proteolytic cleavages by the 
    - and     -secretases (  3  ). The 40-aa form (A    40) 
is the most abundantly produced A     peptide, 
whereas a slightly longer and less abundant 42-aa 
form (A    42) has been implicated as the more 
pathogenic species (  4  ). A    42 forms aggregate 
much more readily than A    40 and other shorter 
A     peptides, and these aggregates are toxic to a 
variety of cells in culture. Despite being a minor 
A     species, A    42 is deposited earlier and more 
consistently than A    40 in the AD brain. 
  Recent studies suggest that soluble A     pep-
tide   “  oligomers  ”   (aggregates and/or protofi-
brils) play an important role in the neuronal 
atrophy and/or disruption of neural circuits in 
the cerebral cortex and hippocampus during AD 
(  5, 6  ). Moreover, the severity of human AD 
correlates closely with the accumulation of A     
oligomers rather than other clinical parameters 
(e.g., senile plaque density) (  7  –  9  ). Recently, 
the existence of such A     oligomers in human 
AD brain was demonstrated by use of a specifi  c 
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    Alzheimer  ’  s disease (AD) is characterized by neuronal atrophy caused by soluble amyloid      
protein (A    ) peptide   “  oligomers  ”   and a microglial-mediated infl  ammatory response elicited 
by extensive amyloid deposition in the brain. We show that CNI-1493, a tetravalent gua-
nylhydrazone with established antiinfl  ammatory properties, interferes with A     assembly 
and protects neuronal cells from the toxic effect of soluble A     oligomers. Administration 
of CNI-1493 to TgCRND8 mice overexpressing human amyloid precursor protein (APP) for 
a treatment period of 8 wk signifi  cantly reduced A     deposition. CNI-1493 treatment 
resulted in 70% reduction of amyloid plaque area in the cortex and 87% reduction in the 
hippocampus of these animals. Administration of CNI-1493 signifi  cantly improved memory 
performance in a cognition task compared with vehicle-treated mice. In vitro analysis of 
CNI-1493 on APP processing in an APP-overexpressing cell line revealed a signifi  cant dose-
dependent decrease of total A     accumulation. This study indicates that the antiinfl  amma-
tory agent CNI-1493 can ameliorate the pathophysiology and cognitive defects in a murine 
model of AD. 1594 CNI-1493 AND ALZHEIMER’S DISEASE   | Bacher et al. 
rons from their toxic eff  ects. To examine the potential ther-
apeutic eff  ects of CNI-1493 in vivo, we used the transgenic 
TgCRND8 mouse model, which overexpresses the human 
APP and manifests many AD features, including cognitive 
impairment and progressive A     plaques formation in their 
brains at   >  12 wk of age. CNI-1493 administration was ini-
tiated when the mice were 4 mo old. As expected, after 2 mo 
antibody that recognizes only oligomeric A    , but not mono-
meric or fi  brillar A     (  10  ). Collectively, these results suggest 
that soluble A     oligomers present a surface-binding region 
that is critical for binding to receptors on neuronal synapses 
and for assembly into amyloid fi  brils. In addition to A     de-
position, neurofi  brillary tangle accumulation, and neuronal 
loss, the end-stage pathology of AD is also notable for the 
presence of numerous cellular and molecular markers of an 
infl  ammatory response that is often associated with the A     
deposits (  11  ). Accordingly, antiinfl  ammatory drugs have been 
suggested to be benefi  cial agents in AD therapy (  12  ). 
  We use an ELISA-based assay to screen for compounds 
that might interfere with the binding between A     oligomer 
and the anti-A     oligomer antibody. The lead molecule iden-
tifi  ed with this screen was CNI-1493, a tetravalent guanylhy-
drazone with well-characterized antiinfl  ammatory activities 
(  13  ). Systemic administration of CNI-1493 is eff  ective in the 
treatment of experimental autoimmune encephalomyelitis, 
cerebral ischemia, and arthritis (  14  –  16  ). We show that CNI-
1493 administration in the APP-expressing TgCRND8 trans-
genic mice signifi  cantly improves memory performance and 
suppresses the development of amyloid pathology. 
    RESULTS AND DISCUSSION   
  CNI-1493 is a surface-directed A     oligomer-binding 
antagonist and is a neuroprotective agent 
  Because anti-A     oligomer antibodies block the toxicity of the 
  “  A     oligomer  ”   antigen, we hypothesized that compounds 
that interfere with A     oligomer formation and its anti-
body binding may also interfere with A     oligomer receptor 
binding and/or assembly into amyloid fi  bril. Accordingly, 
we screened a library of small molecules and found that 
CNI-1493 binds to A    -oligomer and interferes with its rec-
ognition by anti-A     oligomer antibodies (  Fig. 1 A  ).   To ad-
dress the question of how CNI-1493 interferes with the A     
oligomer recognition, we performed electronmicroscopy of 
A     oligomers treated with CNI-1493. As shown in   Fig. 1 B  , 
CNI-1493 disrupts the A     oligomer. To examine whether 
the new form of A    /CNI-1493 is toxic compared with the 
A     oligomers, we tested the toxicity of A     treated with CNI-
1493 in the SH-SY5Y neuroblastoma cell line using MTT. As 
anticipated, the soluble oligomers are toxic (  10  ). Strikingly, 
soluble oligomers treated with CNI-1493 completely lack 
A     toxicity (  Fig. 1 C  ). Similar neuroprotection was observed 
in primary neurons: 90 versus 10% survival in those treated 
with A     oligomer in the presence and absence of CNI-1493, 
respectively (unpublished data). Of note, the neuroprotec-
tive eff  ects of CNI-1493 are specifi  c to A     oligomer, as evi-
denced by lack of protection of neuroblastoma cell line when 
exposed to staurosporine (Fig. S1, available at http://www
.jem.org/cgi/content/full/jem.20060467/DC1). 
  CNI-1493 prevents the formation of A     plaques in APP 
TgCRND8 transgenic mice 
  Collectively, the aforementioned experiments indicate that 
CNI-1493 both interferes with A     assembly and protects neu-
    Figure 1.     CNI-1493 dose-dependently inhibited A     oligomer for-
mation and A     oligomer cell toxicity.   (A) CNI-1493 inhibits A     oligo-
mer formation in vitro as quantifi  ed by direct ELISA using anti-A    
oligomer antibody as described in methods. Control without CNI-1493. 
(B) CNI-1493 alters the A     oligomer  fi  brillation state. A     42  oligomers 
were incubated with CNI-1493 at a 10:1 ratio (A     oligomer/CNI-1493) 
for 20 min. The mixture (2   μ  l) was absorbed onto 200 mesh Nickle carbon, 
negatively stained with 2% uranyl acetate, and viewed with a micro-
scope. (C) CNI-1493 dose-dependently inhibits cytotoxicity of A     oligo-
mers on SH-SY5Y cells as assessed using MTT assay. Control 2.5   μ  M 
without CNI-1493, other samples were 2.5   μ  M A     oligomers  incubated 
for 15 min with the indicated concentration of CNI-1493. Error bars rep-
resent the SD. Bars, 200 nm.     JEM VOL. 205, July 7, 2008  1595
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the brains of CNI-1493  –  treated mice as compared with 
vehicle-treated mice (Fig. S2). 
  CNI-1493 deactivates microglia cells in APP TgCRND8 
transgenic mice 
  The mechanisms by which CNI-1493, which is an antiin-
fl  ammatory agent as well as an amyloid-disrupting assembly 
agent, aff  ects AD sequelae are likely to be complex and di-
verse. It has been suggested, however, that one mechanism 
through which other antiinfl  ammatory agents (e.g., nonste-
roidal antiinfl  ammatory drugs [NSAIDs]) exert their thera-
peutic benefi  t is through microglia suppression. CNI-1493  ’  s 
role as an antiinfl  ammatory agent has been well established 
(  13  ), and it has been shown to be eff  ective in animal models 
of multiple sclerosis, cerebral ischemia, and arthritis (  14  –  16  ). 
To examine CNI-1493  ’  s eff  ect on microglia in the context of 
AD, we evaluated microglia activation by analyzing the ex-
pression of the microglial surface marker F4/80, which is ele-
vated after activation of these cells ( 19  ). We obtained a decrease 
of F4/80 signal within the brain cytosol of all CNI-1493  –
  treated animals in comparison with control animals (  Fig. 4  ).   
of treatment (6 mo of age), vehicle-treated mice devel-
oped significant A     plaque formations (  Fig. 2 and Fig. 3  ).     
  Amyloid deposition was signifi  cantly decreased in mice that 
received CNI-1493 (plaque number divided by the area of 
interest in square mm was reduced within the cortex by 
57% and within the hippocampus by 60% compared with 
vehicle-treated animals; P = 0.016). This eff  ect by CNI-
1493 was even more pronounced when expressed as a re-
duction of plaque area ratio (area of the plaque in square 
micrometers divided by the area of interest in square mil-
limeters). We obtained a reduction of 70% within cortex 
and of 86% within the hippocampus compared with vehi-
cle-treated animals. Significantly, the magnitude of the 
CNI-1493  –  mediated decrease in A     plaques was not only 
higher than that reported for the NSAID ibuprofen but was 
also reached in only 2 mo of treatment, compared with ibu-
profen treatment of 4 or 6 mo in Tg2576 APP transgenic 
mice (  17, 18  ). 
  CNI-1493 effect on soluble A     content in APP TgCRND8 
transgenic mice 
  After demonstrating a potent eff  ect of CNI-1493 on plaque 
deposition in a relatively short treatment period of 2 mo, we 
next analyzed the brain cytosol fractions for a possible CNI-
1493  –  dependent regulation of soluble A    . As determined by 
immunoblot analysis, soluble A     was signifi  cantly reduced in 
    Figure 2.     CNI-1493 suppresses A     plaque formation in transgenic 
APP TgCRND8 mice.   Sagittal sections from vehicle- or CNI-1493  –
  treated mice were stained for A     using the mouse anti  –  human A    
monoclonal antibody 6F/3D after 2 mo of treatment. Bar, 500   μ  m.     
    Figure 3.     Quantitation of A     staining formation reveals a pro-
found reduction of plaque deposition in the CNI-1493  –  treated 
TgCRND8 mice relative to that seen in the vehicle-treated mice.  
CNI-1493 reduced the plaque density in the cortex by 57% (top left; P = 
0.016), and in hippocampus by 60% (bottom left; P = 0.016). CNI-1493 
reduced plaque area in cortex by 70% (top right; P = 0.016), and in hippo-
campus by 86% (bottom right; P = 0.016). Digital images from cortex and 
hippocampus were obtained and analyzed with iSIS analysis Auto Soft-
ware 3.2. Plaque number was calculated by the number of plaques divided 
by the area of interest in square millimeter. The plaque area density was 
computed and expressed as plaque area in square micrometer per area of 
interest in square millimeters. Statistics, Mann-Whitney U-Tests (two-
tailed); control,   n   = 5; CNI-1493,   n   = 4. Error bars represent the SEM.     1596 CNI-1493 AND ALZHEIMER’S DISEASE   | Bacher et al. 
digm, mice are known to also manifest fear of novel objects, 
which interferes with the required object exploration (  22  ). 
Therefore, the experiment was performed on two consecu-
tive days: on day 1, the mice acclimated to the experimental 
environment; on day 2, we made the experimental observa-
tions. Accordingly, the purpose of this study was not to mea-
sure changes longitudinally treated from baseline to follow up, 
but rather to compare the CNI-1493  –   and placebo-treated 
groups once the mice were acclimated to the test situation. 
We measured the recognition index (defi  ned in the Materials 
and methods) for both the number and time of explorations. 
  On the fi  rst day of analysis, we observed no statistical 
diff   erences between the CNI-1493  –   and placebo-treated 
animals in the recognition indices for either recognition in-
dex for number of exploration (0.64   ±   0.07 vs. 0.64   ±   0.09, 
respectively; P = 0.99) or recognition index for time of ex-
ploration (0.65   ±   0.07 vs. 0.64   ±   0.08, respectively; P = 
0.94). On day 2, the CNI-1493  –  treated animals tended to 
investigate more novel objects (recognition index for num-
ber of exploration: 0.68   ±   0.06 vs. 0.50   ±   0.07, respec-
tively; P = 0.061) and spent signifi  cantly more time with 
the novel objects (recognition index for time of explora-
tion: 0.74   ±   0.05 vs. 0.52   ±   0.08, respectively; P = 0.024) 
than placebo-treated animals (  Fig. 6  ). Collectively, these data 
indicate that CNI-1493 treatment is therapeutic in an animal 
model of AD. CNI-1493 treatment not only decreases 
  The CNI-1493  –  dependent decrease in total A     in N2A cells 
is unrelated to secretase activities 
  Several NSAIDs have recently been reported to selectively 
regulate the processing of APP, and it has been argued that 
this eff  ect may underlie their benefi  cial eff  ects in AD (  20  ). 
NSAID treatment of APP-overexpressing cells was reported 
to result in a preferential reduction in the production of A    42 
and a parallel increase in A    38, although it had no eff  ect on 
A    40 (  20  ). 
  In this study, we tested whether CNI-1493 altered total 
A     production in N2a cells overexpressing human APP. 
CNI-1493 treatment resulted in a dramatic and dose-de-
pendent reduction in the levels of total A     secreted into the 
medium (  Fig. 5 A  ).   This result clearly implies that the CNI-
1493 eff  ect on APP processing is not restricted to reduction 
of A    42 but also includes the reduction of A    40. The ob-
served decrease of total A     was not accompanied by re-
duced levels of APP production (  Fig. 6 D  ).   Furthermore, 
CNI-1493 had no eff  ect on the     - or     -secretase  –  mediated 
cleavage of APP (  Fig. 6, B and C  ), which has recently been 
proposed for the mode of action of A     reduction by ibu-
profen (  17  ). 
  CNI-1493 did not affect spatial memory in 
TgCRND8 AD mice 
  Spatial memory was measured using the Barnes maze (  21  ). 
Both groups, CNI-1493  –   and placebo-treated mice, showed 
a reduction in time taken, path length covered, and errors 
made, indicating spatial memory processes (  21  ). However, 
analysis of areas under the learning curves as an integrated 
measure to compare the learning performance did not reveal 
any signifi  cant diff  erences between treatment groups (unpub-
lished data). 
  CNI-1493 treatment preserves object recognition memory 
in TgCRND8 AD mice 
  To measure object recognition memory, mice were observed 
after presentation with familiar and novel objects. In this para-
    Figure 4.     CNI-1493 suppresses microglia activation as assessed by 
reduced surface marker expression.   60   μ  g protein were separated by 
precast NuPAGE Novex 4  –  12% Bis-Tris gels and transferred onto nitrocel-
lulose membranes using the XCell II blot system. The activation of glial 
cells was assessed by staining for the macrophage activation with anti-
bodies against the F4/80 antigen. Immunoblot analysis revealed a decline 
of F4/80 in all CNI-1493 animals. Equal protein loading was assessed by 
reprobing the membrane with monoclonal antibodies against GAPDH.     
    Figure 5.     Effect of CNI-1493 on APP processing in N2a cells ex-
pressing wild type APP695.   Cells were treated for 24 h with the indi-
cated concentrations of CNI-1493. Medium was changed and drug 
treatment was continued for an additional 4 h to allow A     secretion. 
Total secreted A     (total  sA   ) was analyzed by immunoblot using 6E10 
antibody (a). APP C-terminal fragments, C99 (b), and C83 (c) were ana-
lyzed using 6E10 and R1 antibodies, respectively. Full-length APP (d) was 
tested with antibodies LN27.     JEM VOL. 205, July 7, 2008  1597
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antiserum (1:2,000 dilution in 5% nonfat milk/TBS-T) was added and incu-
bated for 1 h at 37  °  C. The plates were washed three times with PBS-T and 
100   μ  l horseradish peroxidase  –  conjugated anti  –  rabbit IgG (diluted 1:10,000 
in 5% nonfat milk/TBS-T; Promega) was added and incubated for 1 h at 
37  °  C. The plates were washed three times with PBS-T and developed using 
3,3    ,5,5    -tetramethylbenzidine (KP). The reaction was stopped with 100   μ  l 
1 M HCl and the plates were read at 450 nm. 
  Animals.     All animal procedures were approved by the offi   ce of the district 
president and the Institutional Animal Care and Use Committee for the Uni-
versity of Munster. We used the TgCRND8 mouse line (courtesy of D. 
Westaway, University of Toronto, Toronto, Canada). TgCRND8 mice en-
code a double-mutant form of APP 695 (KM670/671NL+V717F) under the 
control of the PrP gene promoter (  24  ). Thiofl  avine S  –  positive A     amyloid 
deposits are present at 3 mo, with dense-cored plaques and neuritic pathol-
ogy evident from 5 mo of age. TgCRND8 mice exhibit 3,200  –  4,600 pmol 
of A     per gram of brain at age 6 mo, with an excess of A     42 over A     40. 
  Drug treatment of TgCRND8 mice.     10 APP transgenic TgCRND8 
mice at 4 mo of age received an i.p. injection of either 200   μ  l placebo or 
200   μ  l containing 200   μ  g (8 mg/kg) CNI-1493 twice a week for 8 wk. One 
animal of the CNI-1493 group died before completion of the 16 injections 
and was excluded from further analysis. Mice were housed in groups of 3  –  4 
animals in standard (37(l)   ×   21 (w)   ×   15 (h) cm) cages accompanied by wild-
type littermates. At the end of the experimental period, animals were killed 
and the brain hemispheres were separated along the midline. One hemi-
sphere was fi  xed in 4% buff  ered formaldehyde for 24 h, followed by dehy-
dration and paraffi   n embedding. The other hemisphere was immediately 
snap-frozen in liquid nitrogen and kept at     80  °  C until use. 
  Electron microscopy studies.     A     oligomers were prepared at a concen-
tration of 40  –  55   μ  M as previously described (  10  ). A     oligomers were incu-
bated with CNI-1493 at 1:10 ratios for 20 min with mixing. 2   μ  l of this 
solution were adsorbed onto 200 mesh Nickle carbon  –   and formvar-coated 
grids, air dried, and washed for 30 s in distilled water. The samples were neg-
atively stained with 2% uranyl acetate (Ted Pella, Inc.) for 2 min and viewed 
with a 10CR microscope (80 kV; Carl Zeiss, Inc.). 
  Toxicity assays.     MTT toxicity assay was performed as previously described 
(  10  ) using SH-SY5Y human neuroblastoma cells. Cells were treated with A     
oligomers at a fi  nal concentration of 2.5   μ  M, and samples with CNI-1493 
were incubated for 15 min before treatment. Each data point was determined 
in hexaplicate. 
  Immunohistochemistry.     Three pairs of 2-  μ  m sagittal brain sections of 
each transgenic animal were stained for A     immunoreactivity. The pairs (10   μ  m 
distance) were situated 100, 200, and 300   μ  m lateral from the midsagittal 
fi  ssure. All slices were pretreated with formic acid and automatically stained 
in a TechMate Instrument (Dako) with 6F/3D anti-A     monoclonal anti-
body to residues 8  –  17 (Dako; 1:100). For further steps, the StreptABC 
complex/horseradish peroxidase  –  conjugated   “  Duet  ”   anti  –  mouse/  –  rabbit 
antibody kit (Dako) was used and developed with 3, 3    -diaminobenzidine as 
chromogen. Counterstaining was performed with hematoxylin. All slides 
were stained in two consecutive procedures, making sure that brains of both 
experimental groups were equally distributed in both procedures. 
  Image analysis.     To quantify A     plaque burden, cortices and hippocampus 
of all stained sections were digitalized by a ColorView II, 3, 3 Mega Pixel 
charge-coupled device camera under constant light and fi  lter settings. Color 
images were converted to grayscale to obtain the best contrast between posi-
tive immunoreactivity and background. A constant threshold was chosen for 
all images to detect immunoreactive staining. Morphometric measurements 
were performed using SIS analysis Auto Software 3.2 (Soft Imaging System). 
The total number and size of plaques was related to the total area analyzed. 
amyloid plaque formation but also preserves the cogni-
tive ability of the mice to investigate their surroundings 
more fully. 
  The major fi  nding of this study is the effi   cacy of the 
potent macrophage deactivator CNI-1493 in a murine A     
plaque deposition model. CNI-1493 not only suppresses 
the development of A     plaques but also improves cogni-
tive function after 2 mo of treatment in TgCRND8 mice, 
which overexpress the human APP. As anticipated, CNI-
1493 treatment is accompanied by microglial deactivation. 
Moreover, our in vitro analysis of CNI-1493 treatment on 
APP processing in an APP-overexpressing cell line sug-
gests a profound dose-dependent decrease of total A     se-
cretion. This eff  ect appears to be completely separate from 
both the production of APP and altered     - or     -secretase 
activities. Thus, CNI-1493 may have a dual benefi  cial role 
in mice by inhibiting microglial activation and by promot-
ing A     clearance. Although further work will be needed 
to determine whether these two mechanisms of action 
are causally linked, the results presented herein identify 
the antiinflammatory agent CNI-1493 as a very promising 
candidate for the treatment and prevention of AD in clini-
cal trials. 
    MATERIALS AND METHODS   
  CNI-1493.     CNI-1493 was synthesized as previously described (  23  )  .   
  ELISA assay.     A     42 oligomers (0.3 mg A    /ml H  2  O) were prepared with 
and without CNI-1493, as described previously (  10  ). Samples were diluted 
to 50 ng/100   μ  l in coating buff  er (0.1 M sodium bicarbonate, pH 9.6), and 
100   μ  l of the samples were added to wells of 96-well microplates, incubated 
for 1 h at 37  °  C, washed three times with TBS containing 0.01% Tween 20 
(TBS-T), and then blocked for 2 h at 37  °  C with 10% BSA/TBS-T. The 
plates were washed three times with PBS-T and 100   μ  l of anti-A     oligomer 
    Figure 6.     Novel object task.   The recognition indices (RI) for number 
and length of time spent exploring the novel object is given for control-
treated (shaded bars) and CNI-1493  –  treated (open bars) animals. The RI 
represents the proportion of object exploration that was spent exploring 
the novel object. Statistics, two sample Student  ’  s   t   test; RiN, P = 0.061; RiT, 
P = 0.024; Control,   n   = 12; CNI-1493,   n   = 13. Error bars represent the SEM.     1598 CNI-1493 AND ALZHEIMER’S DISEASE   | Bacher et al. 
on the center of the platform and time taken, path length covered, and errors 
made (exploring wrong holes) were recorded by a tracking system until the 
mice escaped from the platform by entering the target hole that led back to 
their homecage, which was placed below the platform. The test was repeated 
twice a day on 5 consecutive days, allowing time to derive learning curves for 
the aforementioned measures. Details are available in a previous study (  27  ). 
  Novel object task.     Object recognition memory was analyzed with the 
novel object task (  28  ). The test is based upon the tendency of mice to inves-
tigate a novel object rather than a familiar one. To facilitate exploration mice 
were handled 1 wk before the test and additionally habituated to the test 
arena (30   ×   30 cm plywood box, with walls 40 cm high) for 5 min per day 
over a period of 3 d before testing. The task was independently conducted 
two times on two consecutive days with mice being 145   ±   3 d of age. In a 
fi  rst trial (training phase) on each day the mice were allowed to explore two 
similar objects for 5 min. After 1 h, the mouse again was placed into the 
open fi  eld now containing one object similar to both objects presented in 
the fi  rst trial and one novel object (choice phase). A total of fi  ve diff  erent 
objects made of biologically neutral material, such as plastic or metal, were 
used. The objects were not known to have any ethological signifi  cance for 
the mice, and they were never associated with a reinforcer, as recommended 
by Ennaceur (  29  ). To avoid object or place preferences, place and novelty 
status was changed for each object in regular intervals. Fecal boli were re-
moved, and the walls and the fl  oor of the open fi  eld arena were cleaned with 
ethanol (70%) after each tested animal. Number and length of time spent ex-
ploring the objects were recorded using the   “  Novel Object Task  ”   software 
and a handheld computer (http://www.phenotyping.com/not.html). Mice 
that did not explore any of the objects in either the training phase or the 
choice phase could not be analyzed regarding recognition processes, and thus 
were excluded from the analysis of learning behavior on this test day (day 1: 
2 CNI-1493-, 2 placebo-treated mice; day 2: 1 CNI-1493-, 2 placebo-
treated mice). To compare the performance of both treatment groups, the 
recognition indices were calculated as follows: RiN, number of exploration 
of novel object/total number of object explorations; RiT, time spent explor-
ing novel object/total time spent exploring objects. Indices above chance 
level (0.5) refl  ect a preference for the novel object over the known object, 
and thus indicate object recognition memory. 
  Statistics.     Data were analyzed using either Student  ’  s   t   tests or, when datasets 
showed a non-Gaussian distribution, nonparametric Mann-Whitney   U   tests 
were applied (  30  ). A signifi  cance-level (    ) of 0.05 was selected. All tests 
were performed two sided. 
  Online supplemental material.     Fig. S1 shows that CNI-1493 does not 
prevent staurosporine-induced cytotoxicity. Fig. S2 shows that CNI-
1493 inhibits soluble A     formation in transgenic APP TgCRND8 mice. 
The online version of this article is available at http://www.jem.org/cgi/
content/full/jem.20060467/DC1. 
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